Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06269484 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06269484: Completed Phase 2 study, sponsored by AstraZeneca.
NCT06269484 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 73 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06269484, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.
Primary Outcome
Cumulative number of subjects with event of composite fluid retention endpoint
Interventions
- DRUG Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
- DRUG Zibotentan + placebo (placebo matching dapagliflozin tablet)
- DRUG Zibotentan + dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 2 |
What the finished NCT06269484 record still lists
NCT06269484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) is the first listed.
NCT06269484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06269484 about?
NCT06269484 is a clinical study titled "A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK". This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patient...
What is the current status of trial NCT06269484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2024-02-15. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT06269484?
The interventions under investigation include: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) (DRUG), Zibotentan + placebo (placebo matching dapagliflozin tablet) (DRUG), Zibotentan + dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06269484?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06269484's enrollment target sits among peer trials
73 924th of 2000 higher than 1,076 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI